Revium Rx is a pre-clinical stage biopharmaceutical company focused on the development and commercialization of innovative nanoparticle-based therapies. The company leverages advanced lipid-based delivery systems to enhance the safety, efficacy, and clinical utility of established therapeutics, with applications in infectious diseases, oncology, and vaccination. Its core strategy involves creating smarter, more targeted treatments that improve drug delivery to diseased tissues while minimizing systemic exposure and potential side effects.

Revium Rx generates revenue through the development and potential commercialization of proprietary nanoparticle-based drug candidates, which are designed to deliver therapeutic agents to specific targets in the body. The company's primary product candidates include nano-formulations of antibiotics and angiotensin receptor blockers, as well as a novel immunization platform, all aimed at addressing unmet medical needs in areas such as antimicrobial resistance and solid tumors. Revenue will be derived from future product sales, licensing agreements, and potential partnerships once candidates receive regulatory approval and reach the market.

The company operates through the following segments:

• Nano-Mupirocin: This segment focuses on developing a nanoparticle-based formulation of the antibiotic mupirocin for systemic use. The candidate is designed to overcome the limitations of topical mupirocin by enabling intravenous delivery for life-threatening infections caused by antibiotic-resistant bacteria such as MRSA, VRE, and resistant gonorrhea. Preclinical studies have shown promising results in murine and rabbit models, demonstrating reduced bacterial loads and improved pharmacokinetic profiles.

• Nano-Candesartan: This segment is developing a nanoparticle-based formulation of the angiotensin receptor blocker candesartan for intravenous administration. The candidate is being evaluated as a combination therapy to enhance the efficacy of standard anticancer treatments, with an initial focus on pancreatic ductal adenocarcinoma. Preclinical research suggests potential benefits in modulating the tumor microenvironment and improving drug delivery without systemic blood pressure effects.

• Liposomal Protein-Loaded Technology (LPLT): This segment involves a novel immunization approach using lipid-based nanoparticles to deliver protein antigens for vaccine development. The platform is being evaluated for applications against viruses such as SARS-CoV-2 and West Nile Virus, with preclinical studies indicating potential for improved immune response and durability. The technology aims to provide broader protection and longer-lasting immunity compared to existing vaccine platforms.

Revium Rx operates in the competitive biopharmaceutical industry, where it faces competition from established pharmaceutical companies and emerging biotech firms developing similar nanoparticle-based therapies. The company's competitive advantages stem from its proprietary lipid-based delivery technology, exclusive licensing agreements with Yissum, and preclinical data supporting enhanced drug targeting and reduced toxicity. Its focus on high unmet medical needs, such as antimicrobial-resistant infections and aggressive cancers, positions it to address gaps where current therapies are limited or ineffective.

Revium Rx serves patients suffering from serious medical conditions, including those with antibiotic-resistant infections, advanced cancers, and individuals requiring vaccination against viral threats. The company's target customer base includes healthcare providers, hospitals, and public health systems seeking innovative treatments for diseases with limited therapeutic options, particularly in the areas of antimicrobial resistance and oncology.